Note: Ingredients listed on restricted chemical lists
EC/CAS
200-210-4/54-64-8
Name of the chemical
Sodium o-(ethylmercurithio)benzoate
Concentration
>=0,0025-< >=0,1%
General Information
Version
1.1
Revision date
2022-12-05
Product name
Gallimune ND, injectable solution
Product Synonyms
Gallimune ND with: Newcastle disease virus (Ulster 2C strain) inactivated
1.2.1 Relevant identified uses
Veterinary product
1.2.2. Uses advised against
Safety Data Sheet only for the professional user., For veteri- on use nary use only, Refer to the product insert for complete instruc- tions on usage
Emergency telephone
+498007790900, +1 703-527-3887, +49800 1817059
Icons in SDS
Company Information
company name
Boehringer Ing. Pharma GmbH & Co. KG
e-mail address of the competent person responsible for the Safety Data Sheet
EHS-Services@Boehringer-Ingelheim.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H304
Hazard statements
Code
Statements
H304
May be fatal if swallowed and enters airways
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Danger
Hazard statements
H304 May be fatal if swallowed and enters airways.
Response
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER/ doctor. P331 Do NOT induce vomiting.
Storage
P405 Store locked up.
Disposal
P501 Dispose of contents/ container to an approved waste disposal plant.
Hazardous Ingredients
White mineral oil (petroleum)
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regu- lation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) The pharmacological effect of the medicament has to be considered (see package leaflet).
2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008) Aspiration hazard, Category 1 H304: May be fatal if swallowed and enters air- ways.
